PRLD · Prelude Therapeutics Inc
United States · RS rating 56 · As of 2026-11-03
| Price | 3.78 USD |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 56 / 57 / 35 / 96 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 35 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -7.7% |
| Sales growth Q/Q | -13.2% |
| Distance from 52-week high | +43.0% |
| Market cap (USD) | $276.6M |